Multiple news sources are reporting that persons closely familiar with the Johnson & Johnson (J&J) DePuy ASR hip implant litigation say that the New Jersey-based pharmaceutical giant has reached settlements with three plaintiffs in the first product liability lawsuits slated for trial in state court.
About two years ago, New Jersey company Johnson & Johnson made the widely-publicized decision to recall the ASR artificial hip manufactured and sold by DePuy Orthopaedics, a unit of J&J. The company set aside $3 billion to compensate people who had filed personal injury lawsuits in connection with the defective products, and seemed to acknowledge the danger of metal-on-metal artificial hips.
Bergen County residents who have suffered injuries from faulty DePuy hip replacements or other defective Johnson & Johnson products will likely be interested to learn that J&J recently set aside $600 million in preparation for a potential settlement over kickbacks allegations. This is in addition to the $5.3 billion that has reportedly already been reserved for potential products liability and kickback claims in relation to other J&J medications and medical devices.
Slow and steady seems to be the name of the game in the main personal injury lawsuit against DePuy Orthopaedics, a division of New Jersey company Johnson & Johnson, over its faulty artificial hip replacement products.
According to a recently released document, New Jersey company Johnson & Johnson began taking action to phase out the use of its metal-on-metal artificial hips just weeks after the receiving a letter from U.S. Food and Drug Administration. In that letter, the agency reportedly turned down Johnson's application to sell the medical product in the United States, and told the company to submit additional safety data if it wanted to pursue the application.
In recent weeks, we have written extensively on the issues surrounding the DePuy Orthopaedics articular surface replacement (ASR) metal-on-metal hip replacement joints. Essentially, these faulty medical products have caused thousands of people in New Jersey and throughout the country to suffer debilitating pain and lasting injury as a result of friction in the joint's metal components.
Earlier this week, we began an in-depth look into the convoluted process by which Johnson & Johnson and its unit DePuy Orthopaedics sought FDA approval for its articular surface replacement devices, or ASRs. Initially, the FDA rejected the medical product, stating that additional clinical study was necessary to determine whether the product was safe.
New documents have revealed that DePuy Orthopaedics, a unit of New Jersey-based Johnson & Johnson, continued to sell faulty hip replacement joints internationally after they were rejected for sale by the U.S. Food and Drug Administration. At the same time, DePuy sold a similar defective product in the U.S. after was approved through the FDA's 501(k) loophole, which we detailed extensively in a previous product liability blog post.
Recently, the faulty metal-on-metal hip replacement joints manufactured by DePuy Orthopaedics, a unit of New Jersey-based Johnson & Johnson, have become the subject of scrutiny and debate after causing pain and injury to thousands of patients. According to a few new studies, those defective products may continue to cause harm long after they are removed from the body.
Earlier this week, we wrote about the recent influx of product liability lawsuits against New Jersey-based Johnson & Johnson regarding its vaginal mesh implant products, which have resulted in injury and death in hundreds of women throughout the country. The vaginal mesh suits are not the only litigation facing Johnson & Johnson at this time. The company is also defending itself against a growing class action products liability lawsuit after "mechanical failure" forced the recall of hundreds of artificial joints.